PL335934A1 - Solvent system of increased penetration into pharmaceutical compounds - Google Patents
Solvent system of increased penetration into pharmaceutical compoundsInfo
- Publication number
- PL335934A1 PL335934A1 PL98335934A PL33593498A PL335934A1 PL 335934 A1 PL335934 A1 PL 335934A1 PL 98335934 A PL98335934 A PL 98335934A PL 33593498 A PL33593498 A PL 33593498A PL 335934 A1 PL335934 A1 PL 335934A1
- Authority
- PL
- Poland
- Prior art keywords
- solvent system
- pharmaceutical compounds
- increased penetration
- penetration
- increased
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000035515 penetration Effects 0.000 title 1
- 239000002904 solvent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82909197A | 1997-03-31 | 1997-03-31 | |
| PCT/US1998/004033 WO1998043673A1 (en) | 1997-03-31 | 1998-03-03 | Solvent system for enhanced penetration of pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL335934A1 true PL335934A1 (en) | 2000-05-22 |
Family
ID=25253504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98335934A PL335934A1 (en) | 1997-03-31 | 1998-03-03 | Solvent system of increased penetration into pharmaceutical compounds |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0971746A1 (en) |
| JP (1) | JP2001518879A (en) |
| KR (1) | KR19980081207A (en) |
| CN (1) | CN1252003A (en) |
| AR (1) | AR012217A1 (en) |
| AU (1) | AU6677698A (en) |
| BR (1) | BR9811458A (en) |
| CA (1) | CA2285368A1 (en) |
| CO (1) | CO5050328A1 (en) |
| HU (1) | HUP0001739A3 (en) |
| IL (1) | IL132096A0 (en) |
| PL (1) | PL335934A1 (en) |
| WO (1) | WO1998043673A1 (en) |
| ZA (1) | ZA982662B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2232855C (en) * | 1997-04-10 | 2007-10-09 | Roche Consumer Health (Worldwide) Sa | Pharmaceutical formulation |
| WO2000072818A1 (en) * | 1999-05-27 | 2000-12-07 | The Procter & Gamble Company | Topical compositions providing improved treatment of skin or scalp fungal infections |
| GB0103046D0 (en) | 2001-02-07 | 2001-03-21 | Novartis Ag | Organic Compounds |
| IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| JP5435836B2 (en) * | 2003-07-03 | 2014-03-05 | 大正製薬株式会社 | Antifungal composition for external use |
| JP4784051B2 (en) * | 2003-07-03 | 2011-09-28 | 大正製薬株式会社 | Antifungal composition for external use that prevents adsorption to the container |
| DE102005059742A1 (en) | 2005-12-13 | 2007-06-14 | Beiersdorf Ag | Transparent sunscreen |
| US20080032994A1 (en) | 2006-08-03 | 2008-02-07 | Marcel Borgers | Modified azole compounds as antifungal and antibacterial agents |
| WO2009013331A1 (en) * | 2007-07-25 | 2009-01-29 | Ixodes Gmbh | Topical antibiotic composition for the prevention of lyme disease |
| WO2009028495A1 (en) * | 2007-08-27 | 2009-03-05 | Nihon Nohyaku Co., Ltd. | Agent for fungal dermatitis |
| US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
| US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
| US9839611B2 (en) * | 2013-09-10 | 2017-12-12 | Insys Development Company, Inc. | Sublingual buprenorphine spray |
| MY179756A (en) | 2013-10-03 | 2020-11-12 | Dow Pharmaceutical Sciences | Stabilized efinaconazole formulations |
| CN105848719A (en) | 2013-11-22 | 2016-08-10 | 道尔医药科学公司 | Anti-infective methods, compositions, and devices |
| CN115745757B (en) * | 2022-11-07 | 2024-04-26 | 中国人民解放军军事科学院军事医学研究院 | Synthesis of liquid-state polyglycol column arene derivative and application of liquid-state polyglycol column arene derivative in transdermal pharmacodynamic molecule slow release |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2051998T3 (en) * | 1988-02-29 | 1994-07-01 | Pfizer | INCREASING COMPOSITIONS OF THE TRANSDERMAL FLOW. |
| GB8827822D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| CN1106259A (en) * | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition |
-
1998
- 1998-03-03 WO PCT/US1998/004033 patent/WO1998043673A1/en not_active Application Discontinuation
- 1998-03-03 HU HU0001739A patent/HUP0001739A3/en unknown
- 1998-03-03 PL PL98335934A patent/PL335934A1/en unknown
- 1998-03-03 CA CA002285368A patent/CA2285368A1/en not_active Abandoned
- 1998-03-03 BR BR9811458-1A patent/BR9811458A/en not_active Application Discontinuation
- 1998-03-03 AU AU66776/98A patent/AU6677698A/en not_active Abandoned
- 1998-03-03 IL IL13209698A patent/IL132096A0/en unknown
- 1998-03-03 JP JP54163598A patent/JP2001518879A/en active Pending
- 1998-03-03 EP EP98908843A patent/EP0971746A1/en not_active Withdrawn
- 1998-03-03 CN CN98803908A patent/CN1252003A/en active Pending
- 1998-03-30 ZA ZA9802662A patent/ZA982662B/en unknown
- 1998-03-31 CO CO98017937A patent/CO5050328A1/en unknown
- 1998-03-31 AR ARP980101461A patent/AR012217A1/en unknown
- 1998-03-31 KR KR1019980012493A patent/KR19980081207A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR012217A1 (en) | 2000-09-27 |
| CO5050328A1 (en) | 2001-06-27 |
| EP0971746A1 (en) | 2000-01-19 |
| BR9811458A (en) | 2000-09-19 |
| HUP0001739A3 (en) | 2001-04-28 |
| IL132096A0 (en) | 2001-03-19 |
| KR19980081207A (en) | 1998-11-25 |
| AU6677698A (en) | 1998-10-22 |
| ZA982662B (en) | 1999-09-30 |
| HUP0001739A2 (en) | 2000-12-28 |
| CN1252003A (en) | 2000-05-03 |
| WO1998043673A1 (en) | 1998-10-08 |
| JP2001518879A (en) | 2001-10-16 |
| CA2285368A1 (en) | 1998-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9602080D0 (en) | Pharmaceutical compounds | |
| PT892640E (en) | PHARMACEUTICAL COMPOUNDS OF MYCOFENOLATE | |
| EG24044A (en) | pharmaceutical formulation of omeprazole | |
| GB9700504D0 (en) | Pharmaceutical compounds | |
| PL335934A1 (en) | Solvent system of increased penetration into pharmaceutical compounds | |
| EG22250A (en) | Novel pharmaceutical compound | |
| EP0941039A4 (en) | Transdermal administration of ment | |
| GB9722600D0 (en) | Pharmaceutical compositon | |
| EP1003495A4 (en) | Pharmaceutical compounds | |
| GB9609976D0 (en) | Pharmaceutical compounds | |
| GB9716244D0 (en) | Pharmaceutical compounds | |
| GB9621789D0 (en) | Pharmaceutical compounds | |
| AU4330097A (en) | Pharmaceutical compounds | |
| GB9700737D0 (en) | Administration of drugs | |
| IL126050A0 (en) | Sustained-release pharmaceutical formulations containing mizolastin | |
| EP0923564A4 (en) | Pharmaceutical compounds | |
| ZA979329B (en) | Pharmaceutical compounds | |
| ZA98300B (en) | Pharmaceutical compounds | |
| HUP9904328A3 (en) | Solvent extraction of 3-hydroxymethylcephalosporins | |
| GB9626151D0 (en) | Pharmaceutical compounds | |
| GB2360470B (en) | Solvent mixture | |
| HU9700442D0 (en) | Compounds of pharmaceutical activity | |
| GB9717041D0 (en) | Pharmaceutical compounds | |
| ZA987535B (en) | Pharmaceutical compounds | |
| GB9705400D0 (en) | Pharmaceutical compounds |